No biomarkers for antidepressant efficacy in major depressive disorder (MDD) are available
that can reduce patient suffering and healthcare costs from ineffective trials. This dissertation …

Introduction: Individual participant data meta-analyses (IPD-MAs) include the raw data from
relevant randomised clinical trials (RCTs) and involve secondary analyses of the data …

Background This study aimed to examine the efficacy of combining paroxetine and
mirtazapine v. switching to mirtazapine, for patients with major depressive disorder (MDD) …

在第2 周未达到早期改善(early improvement) 的重度抑郁症(major depressive disorder, MDD)
患者继续维持原治疗方案只有3% 能达到临床治愈, 但尽管早期改善有较高的阴性预测值 …

Depression, a major global public health concern and leading cause of disability,
necessitates effective management. This paper, as part of the development of …

Sažetak Depresija je jedan od vodećih uzroka invaliditeta i značajan javno-zdravstveni
izazov, usled čega zahteva efikasan tretman. Ovaj rad predstavlja pregled farmakološkog …

In 2019, regular surveillance of 110 English-language research journals identified 254
studies that met the criteria to become POEMs (patient-oriented evidence that matters) …

Depression is a common and disabling mental disorder. Empirical studies have shown that
depressive symptoms vary substantially according to antecedents and outcome variables …

АННОТАЦИЯ Эксперты рабочих групп Российского кардиологического общества и
Российского общества психиатров, Байкальской и Сибирской психосоматических …

Individualized medicine tailors diagnoses and treatment options on an individual patient
basis. This is a paradigm shift from choosing a treatment based on highest reported efficacy …